Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.
Advertisement

Related Content

Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
Beyond Gleevec: What's Next For Novartis Oncology?
Beyond Gleevec: What's Next For Novartis Oncology?
From Gleevec To Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission
From Gleevec To Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission
Business And Finance, In Brief
Business And Finance, In Brief
Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race

Topics

Advertisement
UsernamePublicRestriction

Register

PS068646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel